Reducing early brain inflammation may ease Alzheimer’s progress. The latest research in animal models explains that targeting early brain inflammation may slow down the progression of Alzheimer’s disease.
The American Association for Anatomy (AAA) had planned to present this research in the annual meeting which was canceled because of the COVID-19 pandemic.
The study was published in The Journal of the Federation of American Societies for Experimental Biology.
The Centres for Disease Control and Prevention (CDC) states that Alzheimer’s disease is a neurodegenerative disease that affects a person’s ability to think. The disease is the most common form of dementia, affecting around 5 million people in the United States as of 2014.
Symptoms can include mild memory loss, difficulty thinking and understanding, mental confusion, personality changes, restlessness, and lack of restraint.
Scientists say that numerous factors, such as a person’s age, genetic profile, and possibly education, diet, and environment are responsible for developing Alzheimer’s. But there is no known cure for Alzheimer’s.
The study author reveals that inflammation is an important component of Alzheimer’s disease which is the body’s defense against infection.
“Starting an intervention at the earliest stage of the disease, when cellular and molecular alterations have already been triggered but major damage to the brain has not yet occurred, could offer a way to reduce the number of people who go on to develop full Alzheimer’s dementia,” Dr. Caterina Scuderi, Assistant Professor of pharmacology and toxicology from Sapienza University of Rome, Italy said.
Caroline Kenny is the senior news reporter for News Fior She covers Science. Caroline graduated from the Honors College at the College of Charleston with bachelor’s degrees in communication and political science. She worked for Science Mag. She was a digital producer for Science Mag. She is a native of Long Island, New York.